Drug Database
AN

antithrombin III (Atenotiv / ATenativ / ATnativ)

✓ Approved

Pfizer, Inc. · SERPINC1 · Cell-based Therapies

What is antithrombin III?

antithrombin III is a cell-based therapies developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAtenotiv, ATenativ, ATnativ
CompanyPfizer, Inc.
Drug ClassCell-based Therapies
Molecular TargetSERPINC1
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Pfizer, Inc.

Mechanism of Action

Molecular Targets

antithrombin III acts on 1 molecular target:

SERPINC1serpin family C member 1 (ATIII, AT3D)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

antithrombin III is developed for 3 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved
Vascular disordersThrombosis✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved

Related Research Articles

PubMedRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2026-07-25

Hemostatic safety profile of estetrol vs. ethinylestradiol in oral contraceptives: a systematic review and meta-analysis.

Lemos Maria Julia MJ, Ferraz Jacqueline Maia JM, Queiroz Laura Fonseca LF, Diniz Alice França AF et al.

To evaluate the hemostatic profile of estetrol/drospirenone (E4/DRSP) compared with ethinylestradiol/drospirenone (EE/DRSP) in adult women. A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed according to PRISMA guidelines. Eligible studies compared E4/DRSP with EE/DRSP in adult women and assessed coagulation, anticoagulation, or fibrinolytic markers. Three RCTs (n=183) met inclusion criteria. Data were extracted independently, and pooled mean differences (MD) were calculated using random-effects models. Compared to EE/DRSP, E4/DRSP was associated with higher protein S activity (MD = 21.23; 95% CI: 11.83 to 30.64; p<0.00001) and lower levels of fibrinogen (MD = -24.17; 95% CI: -39.15 to -9.19; p=0.002), plasminogen (MD = -27.28; 95% CI: -27.28 to - 22.89; p<0.00001), and SHBG (MD = -183.38; 95% CI: -183.38; 95% CI: -210.93 to -155.84; p<0.00001). No significant differences were observed for D-dimer and antithrombin. Protein C activity was higher in the EE group, though this was an isolated finding with limited interpretability. E4/DRSP demonstrates a more favorable hemostatic profile than EE/DRSP, potentially reducing thrombotic risk. Despite the limited number of RCTs, consistency across markers supports E4 as a safer estrogenic component for contraceptive formulations, with implications for women at increased risk of venous thromboembolism.PROSPERO registry: #CRD420251074961.

PMID 42500171
Read full article →
PubMedWorld journal of otorhinolaryngology - head and neck surgery2026-07-25

Draf III in the Acute Phase of Pott's Puffy Tumor: A Scoping Review.

Kakar Sahil S, Ali Haris H, Khan Husnaa Fathima Ali Azamathullah HFAA, Amjad Rameez R et al.

Pott's puffy tumor (PPT) is a rare but serious sequela of frontal sinusitis characterized by osteomyelitis of the frontal bone with subperiosteal abscess formation. Surgical management has traditionally been delayed until resolution of the acute infection. This scoping review evaluates the safety and outcomes of performing "Hot" Draf III (modified Lothrop) surgery during the acute phase of PPT. A review was conducted in accordance with PRISMA guidelines. Literature searches were performed across PubMed, Embase, Scopus, and ClinicalTrials.gov without date restriction. Eligible studies included patients undergoing Draf III surgery acutely (within 28 days of presentation) for PPT. Data were extracted on demographics, surgical approach, complications, and reintervention rates. Pooled analysis was performed using a random-effects model with Freeman-Tukey transformation to stabilize variance. Five studies met the inclusion criteria, encompassing nine patients (seven males, two females; mean age 50.3 years). All underwent acute Draf III surgery, primarily via endoscopic approaches (88.9%). Meta-analysis demonstrated a pooled complication rate of 0% (95% CI: 0%-40%) and a reintervention rate of 3% (95% CI: 0%-71%), with no significant heterogeneity (I² = 0%). "Hot" Draf III surgery appears to be a safe and effective management option for PPT during the acute phase, offering low complication and reintervention rates. While these findings support early surgical intervention, larger, prospective studies are required to validate long-term outcomes and define patient selection criteria.

PMID 42500077
Read full article →
PubMedArthroscopy techniques2026-07-25

L-Shaped Three-Portal Configuration for Arthroscopic Double-Row Suture Repair of Lafosse Type III and IV Subscapularis Tears.

Li Gang G, Shen Feifei F, Sun Wei W, Li Shaobo S et al.

Lafosse type III and IV subscapularis tendon injuries are severe rotator cuff tears. Current repair uses anterolateral, anterior, and lateral portals, which have restricted visualization and difficult maneuverability. This technical note describes an L-shaped three-portal (LST) combination: anterosuperolateral, anteroinferolateral, and anteroinferomedial portals. The L-shaped three-portal configuration establishes an unobstructed surgical field free from bony interference, allowing comprehensive subscapularis tendon exposure. It optimizes anchor insertion angles and suture passing path, promoting accurate anchor fixation and effective suture management. Ultimately, it minimizes surgical complications and improves double-row repair efficiency for Lafosse type III/IV injuries, presenting a secure and efficient approach. This article outlines the technique, highlighting procedural aspects, potential risks, advantages, and limitations.

PMID 42499861
Read full article →
PubMedPhysiological measurement2026-07-25

Direct measurements of alveolar gas in mechanically ventilated humans.

Tusman Gerardo G, Nicolás Matías M, Carmona Alejandro A, Suarez Sipmann Fernando F et al.

The composition of alveolar gases is based on theoretical assumptions. The role of expired samples at the airway opening in representing the true value of mean alveolar gas remains a subject of debate. We hypothesized that phase III of oxygrams and capnograms obtained at the airway opening must be qualitative similar to the one found at the lung acini. The aim of this study is to test this hypothesis, analyzing the phase III of breath-by-breath samples of airway and alveolar gases from mechanically ventilated patients. The study compared expired gases at the airway opening and direct gas samples taken from peripheral lung parenchyma in ventilated patients undergoing thoracic surgery. We used video-assisted lobectomies as a model to get direct alveolar gas samples from the lobe that was removed by surgery. In ten anesthetized patients before lobectomy, the corresponding lung lobe was punctured by a 20G angiocath at ⁓5 mm of depth and then connected via a sampling line to sidestream and mainstream capnographs. An oscillating pattern in synchrony with the mechanical breath cycles was observed in the alveolar CO2 and O2 samples. The alveolar capnograms and oxygrams revealed an absence of phase I, very short phase II, and a similar phase III. The slope of phase III of the expired curves at the airway opening [median 2.20 (inter-quartile range 1.28) mmHg/s] were similar to the one of the alveolar mainstream capnograms [median 2.18 (inter-quartile range 1.24) mmHg/s; p = 0.76]. Our findings suggest that alveolar gas can be reliably sampled at the airway opening. The similarity in the slopes of phase III between airway and alveolar samples highlights the significance of continuous gas diffusion through the alveolar-capillary membrane as well as the presence of convection- and diffusion-dependent inhomogeneities in their origin.

PMID 42497902
Read full article →
PubMedGalen medical journal2026-07-25

Prevalence and Distribution of Sagittal and Vertical Subtypes in Skeletal Class III Malocclusion: A Retrospective Study across Age and Sex Groups :.

Tavakol Davani Shiva S, Tahmasbi Soodeh S, Hassannia Dargah Mohammad M, Lakmazaheri Ehsan E et al.

Skeletal Class III malocclusion causing mandibular prognathism, maxillary retrognathism, or a combination of both, has widely varying prevalence by ethnicity. The objective of this research is to investigate the prevalence of contributing factors in its development across different age and sex groups of Iranians. In this study, 233 lateral cephalograms of patients with skeletal Class III malocclusion who had referred our orthodontics center from 2015 to 2024. In the sagittal dimension, the samples were categorized into four groups: retrognathic maxilla, prognathic mandible, combination, and normal. The prevalence of each condition was analyzed across groups. In case of discrepancies between Steiner and McNamara analyses, final sagittal diagnoses were manually determined. This study examined 233 lateral cephalograms of individuals with skeletal Class III malocclusion, including 101 males (43.3%) and 132 females (56.7%). There was a significant association between the final sagittal relationship diagnosis and the combined age-sex groups (P=0.010), indicating that the distribution of sagittal patterns varies across age and sex subgroups. Mandibular prognathism was the most prevalent condition in all groups except for females aged 7-11, where mandibular prognathism and maxillary retrognathism were equally common. In the vertical dimension, 51.9% of cases had normal facial height. No significant correlation was found between vertical dimension and age or sex (P=0.479). The strongest positive correlation was observed between Sum.o.p and SN.GoMe, as well as Wits and A. NPPD, while the strongest negative correlations involved Jarabak.index with Sum.o.p and SN.GoMe. The results indicated that mandibular prognathism is the predominant cause of skeletal Class III malocclusion, except in females aged 7-11, where maxillary retrognathism is also prevalent. No discernible pattern was detected in vertical classification among age and sex groups. The research shows the significance of employing various diagnostic methods for a thorough assessment. Subsequent research needed to integrate longitudinal studies and advanced imaging techniques to improve diagnostic precision.

PMID 42500694
Read full article →
PubMedTrials2026-07-25

The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) trial-rationale for the selected lower steroid dose.

WHO ACTION Trials Collaborators

Antenatal corticosteroids (ACS), most commonly administered as betamethasone or dexamethasone, remain a cornerstone of care for women at risk of preterm birth. However, the standard 24-mg regimen introduced more than five decades ago has not undergone formal dose-finding evaluation. Emerging concerns regarding possible dose-related adverse effects, particularly among late preterm infants subsequently born at term, have renewed interest in optimizing corticosteroid exposure. Experimental data across species, supported by human pharmacokinetic analyses, indicate that fetal lung maturation is driven by sustained low corticosteroid concentrations rather than high peak levels. This commentary summarizes key experimental, pharmacokinetic, and modelling evidence that informed the selection of the lower-dose betamethasone phosphate regimen evaluated in the WHO ACTION-III trial and explains the scientific rationale for this dosing strategy. Pharmacokinetic modeling indicates that 2 mg betamethasone phosphate administered intramuscularly every 12 h for four doses achieves fetal concentrations within the 1 to 4 ng/mL range identified in experimental studies, while avoiding the supratherapeutic peaks observed with conventional regimens. The ACTION-III trial will evaluate whether this lower dose ACS regimen, chosen on the basis of carefully developed models and clinical studies, maintains clinical efficacy while potentially reducing unnecessary systemic corticosteroid exposure in women at risk of late preterm birth.Trial registration: ISRCTN11434567, registered on 7 June 2021.  https://www.isrctn.com/ISRCTN11434567?q=ACTION-III&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10 .

PMID 42498945
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about antithrombin III